Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238294 | 1.00 | ALOX5 (0.41) | ALOX5MMP13MMP14MAPK14CA12 | |
| SCHEMBL5236069 | 0.91 | ALOX5 (0.38) | ALOX5MMP13MMP14MAPK14CA12 | |
| SCHEMBL5236077 | 0.91 | ALOX5 (0.38) | ALOX5MMP13MMP14MAPK14CA12 | |
| SCHEMBL5236506 | 0.90 | ALOX5 (0.41) | ALOX5MMP13MMP14MAPK14ALDH1A1 | |
| SCHEMBL5233221 | 0.88 | NPC1 (0.31) | OPRD1 | |
| SCHEMBL5233227 | 0.88 | NPC1 (0.31) | OPRD1 | |
| SCHEMBL5230595 | 0.86 | KDM4E (0.43) | PTGS2ALDH1A1KDM4EALKBH1 | |
| SCHEMBL5230600 | 0.86 | KDM4E (0.43) | PTGS2ALDH1A1KDM4EALKBH1 | |
| SCHEMBL5230778 | 0.84 | ALKBH1 (0.41) | PTGS2ALDH1A1KDM4EALKBH1 | |
| SCHEMBL5230782 | 0.84 | ALKBH1 (0.41) | PTGS2ALDH1A1KDM4EALKBH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | claimed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | claimed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | claimed |
| EP-1730116-B1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | ALOX5 1076/4885MMP13 3506/4885MMP14 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.